20 May 2013
Keywords: basf, ends, ph, iii, trial, ancrod, stroke
Article | 03 April 2000
BASF Pharma says that it has discontinued a Phase III clinical trial ofits fibrinogen-lowering drug Viprinex (ancrod), which was being
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
3 April 2000
5 April 2000
© 2013 thepharmaletter.com